In this podcast episode, Medicom’s correspondent covers 6 presentations from the IASLC World Conference on Lung Cancer (WCLC 2021), held virtually 8-14 September 2021, The topics discussed are:
1. Atezolizumab promising for treating NSCLC brain metastases
In treatment-naïve subjects with non-squamous non-small-cell lung cancer (NSCLC) and asymptomatic brain metastases, immune checkpoint inhibitor atezolizumab in combination with carboplatin plus pemetrexed prolonged progression-free survival (PFS) in the phase 2 ATEZO-BRAIN trial.
2. Interim results of nivolumab + rucaparib in SCLC
Interim results of a phase 2 study suggest that patients with extensive-stage small-cell lung cancer (SCLC) and platinum sensitivity may be good candidates for maintenance treatment with immune checkpoint inhibitors (ICI) and poly adenosine diphosphate-ribose polymerase inhibitors (PARPi), in this particular study, nivolumab and rucaparib..
3. Pembrolizumab shows potential in TKI-resistant EGFR+ NSCLC, not ALK+
A small study reported at WCLC 2021 demonstrated a response rate of 42%, a median progression-free survival (PFS) of 8.3 months, and a median overall survival of 22.2 months in patients with recurrent epithelial growth factor receptor-positive non-small-cell lung cancer (NSCLC) treated with pembrolizumab plus carboplatin and pemetrexed.
4. COVID-19 sees decreased lung cancer diagnoses and use of support services in US
The COVID-19 pandemic has impacted lung cancer in multiple ways: rates of cancer diagnosis and treatment has decreased, as has the utilisation of patient support services, the GO2 survey reports.
5. Lung Cancer Europe patient survey identifies gaps in lung cancer care
The lung cancer care pathway can be improved by integrating psychosocial services and increasing awareness of available patient and non-governmental organisations according to a survey by Lung Cancer Europe.
6. New preoperative classification scheme proposed for oligometastatic NSCLC
Researchers have developed a risk classification scheme that, if validated, may inform decision making about patients with oligometastatic non-small–cell lung cancer (NSCLC). The scheme could also help to identify appropriate candidates for involvement in future clinical trials.
Enjoy Listening!
Copyright ©2021 Medicom Medical Publishers
Posted on
Table of Contents: WCLC 2021
Featured articles
Atezolizumab promising for treating NSCLC brain metastases
Novel Therapy Approaches
Atezolizumab promising for treating NSCLC brain metastases
Interim results of nivolumab + rucaparib in SCLC
Pembrolizumab shows potential in TKI-resistant EGFR+ NSCLC, not ALK+
Real-world data shows inferior survival compared with IMpower150 results
NSCLC metastases also benefit from nivolumab + ipilimumab + chemo
Trial explores potential benefit of adding atezolizumab to usual care for mesothelioma
COVID-19
COVID-19 sees decreased lung cancer diagnoses and use of support services in US
Experiences of lung cancer patients during COVID-19: survey finds room for improvement
Evidence-Based Advocacy
GLCC survey: Increased demand for patient-support services during COVID-19 pandemic
Lung Cancer Europe patient survey identifies gaps in lung cancer care
Discrepancies and lack of guideline adherence in EGFR+ NSCLC treatment
Response Predictors
Baseline CD8+ T-cells predict NSCLC immunotherapy safety
Genomic profiling of NSCLC may be predictive of immunotherapy response
New preoperative classification scheme proposed for oligometastatic NSCLC
Prognostic factors in immunotherapy for advanced lung cancer
site created by:
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com